



DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
Silver Spring MD 20993

NDA 021286/S-036

SUPPLEMENT APPROVAL

Daiichi Sankyo, Inc.
Attention: Ms. Kerrie Leigh Nagrod, MSJ
399 Thornall Street, 10th floor
Edison, NJ 08837

Dear Ms. Nagrod:

Please refer to your Supplemental New Drug Application (sNDA) dated and received May 18, 2016, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Benicar (olmesartan medoxomil) 5 mg, 20 mg, and 40 mg Tablets.

This supplemental new drug application provides for labeling revised as follows (additions are marked as underlined text and deletions are marked as ~~striketrough~~ text):

1. In **HIGHLIGHTS**, the following test was added:

-----**RECENT MAJOR CHANGES**-----
Warnings and Precautions (5.6) 11/2016

2. Under **WARNINGS AND PRECAUTIONS**, the following section was added:

5.6 Electrolyte Imbalances
Benicar contains olmesartan, a drug that inhibits the renin-angiotensin system (RAS).
Drugs that inhibit the RAS can cause hyperkalemia. Monitor serum electrolytes
periodically.

3. The Table of Contents was updated.
4. The revision date was updated.

There are no other changes from the last approved package insert.

APPROVAL & LABELING

We have completed our review of this supplemental application and it is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug

registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the package insert, text for the patient package insert, Medication Guide), with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, please call:

Lori Anne Wachter, RN, BSN, RAC
Regulatory Project Manager for Safety
(301) 796-3975

Sincerely,

{See appended electronic signature page}

Mary Ross Southworth, PharmD.
Deputy Director for Safety
Division of Cardiovascular and Renal Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

ENCLOSURE(S):
Content of Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

MARY R SOUTHWORTH
11/01/2016